Discover investment opportunities in Top 30 Stocks Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 30 Stocks Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 30 Stocks Under $1 using our Smart AI Filter.
6 stocks found for "Top 30 Stocks Under $1"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.11 | ±100.0% | — | 0.00% | |||
0.76 | ±100.0% | -0.1 | 0.00% | |||
1.01 | ±72.3% | -3.1 | 0.00% | |||
0.65 | ±93.4% | -1.0 | 0.00% | |||
0.64 | ±100.0% | -0.4 | 0.00% | |||
0.15 | ±100.0% | -0.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: Why might investors consider KXIN for their portfolio?
A: Some investors look at KXIN due to its presence in the electric vehicle sector, which has seen significant interest. However, its low price suggests higher volatility and risk, necessitating careful analysis of its financial metrics and market conditions.
Q: What are the potential risks associated with investing in VTAK?
A: VTAK, like many biotech stocks, carries risks due to dependency on clinical trial results and regulatory approvals. Investors should evaluate its research pipeline and funding stability before investing.
Q: Does NUWE offer growth potential in its sector?
A: NUWE is involved in the biotechnology sector, which could offer growth opportunities due to demand for innovative therapies. However, the company's success heavily depends on its product development and market acceptance.
Q: How has VXRT historically reacted during pandemics or health crises?
A: VXRT, being a biotech company, often experiences increased interest during health crises due to its vaccine-related efforts. Investors may consider tracking its R&D progress and market developments.
Q: What competitive advantages does ONCY provide in the oncology space?
A: ONCY focuses on innovative cancer therapies, potentially offering unique treatment options. The company's competitive edge lies in successful clinical trials and strategic partnerships, but investors should scrutinize its results and competitive landscape.
Q: Is HCTI a viable option for tech sector investors seeking innovation?
A: HCTI specializes in high-tech coatings, catering to various industries. Investors looking for innovation might find its niche appealing, but should consider the company's market position and competition.
Oncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read moreDiscover why Zacks rates Healthcare Triangle as "Underperform", being the first on Wall Street to initiate coverage on the stock. Explore HCTI's heavy reliance on top clients amid liquidity issues and ongoing losses.
Read moreKaixin Auto Holdings (NASDAQ: KXIN) revealed that Beijing Camping Club Sports and Culture Communication Co Ltd (Camping Club) has agreed to order about 20,000 new energy vehicles over the next five years. The value of the order totals RMB6 billion ($938 million).
Read more